Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The apoptosis regulatory machinery is a sophisticated network of proteins and signaling pathways that execute programmed cell death to maintain tissue homeostasis [1]. It is primarily categorized into the intrinsic pathway, which is mediated by mitochondrial outer membrane permeabilization, and the extrinsic pathway, which is triggered by extracellular death ligands [2]. Key components include the Bcl-2 family of proteins, which act as rheostats for cell survival, and the caspase family of proteases that serve as the final executioners of the cell [3]. In oncology, the evasion of this machinery is a hallmark of cancer, often achieved through the overexpression of anti-apoptotic proteins like Bcl-2 or Mcl-1 [4]. Therapeutic intervention involves the use of BH3 mimetics, such as Venetoclax, which bind to and neutralize anti-apoptotic proteins to restore the cell's ability to undergo apoptosis [5]. Conversely, dysregulated over-activation of these pathways is implicated in neurodegenerative diseases and ischemic injury, where preventing cell death is the primary therapeutic goal [6]. Monitoring biomarkers such as cleaved caspase-3 or cytochrome c release is essential for evaluating the efficacy of drugs targeting this machinery [1]. Citations: [1] National Center for Biotechnology Information (NCBI). 'Apoptosis, Programmed Cell Death.' [2] Nature Reviews Molecular Cell Biology. 'The mitochondrial pathway of apoptosis.' [3] UniProt Consortium. 'Bcl-2 family proteins.' [4] Hanahan D, Weinberg RA. 'Hallmarks of Cancer: The Next Generation.' Cell. [5] FDA. 'VENCLEXTA (venetoclax) prescribing information.' [6] PubMed. 'Apoptotic mechanisms in neurodegeneration.'
Induction of programmed cell death by inhibiting anti-apoptotic Bcl-2 family proteins, activating pro-apoptotic effectors (BAX/BAK), or neutralizing Inhibitors of Apoptosis Proteins (IAPs).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apoptosis regulatory machinery.